newsfilter
← Latest News
PR Newswire·

Azitra, Inc. to Present at 2026 BIO International Convention

AZTR
  • Azitra Inc. (NYSE American: AZTR) announced that Cofounder & Chief Operating Officer Travis Whitfill, Ph.D., MPH, will present at the 2026 BIO International Convention.
  • The presentation is scheduled for Tuesday, June 23, 2026, at 4:45 PM PT in Theater 1 at the San Diego Convention Center.
  • Dr. Whitfill will highlight pipeline progress, including the launch of a protein & peptide program for cosmetic & cosmeceutical markets using proprietary filaggrin technologies.
  • During the convention, Dr. Whitfill will hold one-on-one meetings with investors & potential partners to discuss business strategy & milestones.
  • Azitra's lead program ATR-12 utilizes an engineered S. epidermidis strain to treat Netherton syndrome & is currently in a Phase 1b clinical trial.
  • Program ATR-04 uses an engineered S. epidermidis strain for EGFR inhibitor-associated rash & has received FDA Fast Track designation.
  • Azitra holds an open IND for ATR-04 & estimates the target population in the U.S. at approximately 150,000 patients.
  • The company's platform includes a microbial library of ~1,500 bacterial strains augmented by AI & machine learning for drug discovery.
  • The new filaggrin initiative aims to leverage Azitra's genetic engineering platform to manufacture proteins & peptides for consumer & research markets.
  • The press release includes forward-looking statements regarding trial data timing, safety results, & regulatory strategies subject to various risks & uncertainties.